Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36

Chem Commun (Camb). 2020 Sep 15;56(73):10706-10709. doi: 10.1039/d0cc02174a.

Abstract

Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(iv) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • CD36 Antigens / metabolism
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Drug Resistance, Neoplasm / drug effects*
  • Female
  • HEK293 Cells
  • Humans
  • Organoplatinum Compounds / pharmacology*
  • Ovarian Neoplasms / drug therapy*
  • Prodrugs / pharmacology*

Substances

  • Antineoplastic Agents
  • CD36 Antigens
  • CD36 protein, human
  • Organoplatinum Compounds
  • Prodrugs
  • Cisplatin